SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-154347
Filing Date
2024-06-04
Accepted
2024-06-04 16:57:02
Documents
14
Period of Report
2024-06-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d821949d8k.htm   iXBRL 8-K 25880
2 EX-1.1 d821949dex11.htm EX-1.1 263274
  Complete submission text file 0001193125-24-154347.txt   467432

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rprx-20240603.xsd EX-101.SCH 2856
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rprx-20240603_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rprx-20240603_pre.xml EX-101.PRE 10816
18 EXTRACTED XBRL INSTANCE DOCUMENT d821949d8k_htm.xml XML 3727
Mailing Address 110 EAST 59TH STREET NEW YORK NY 10022
Business Address 110 EAST 59TH STREET NEW YORK NY 10022 (212) 883-0200
Royalty Pharma plc (Filer) CIK: 0001802768 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39329 | Film No.: 241019084
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)